Prescribing For
Found 8 free book(s)
YERVOY U.S. Prescribing Information - BMS
packageinserts.bms.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. YERVOY (ipilimumab) injection, for intravenous use . Initial U.S. Approval: 2011 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION A single …
www.merck.comSee Full Prescribing Information for instructions on the preparation of solutions. (2.3) For doses above 1.5 g, reconstitute a second vial in the same manner as the first one, withdraw an appropriate volume (per Table 3 in the Full Prescribing Information), and add to the same infusion bag. (2.3)
HIGHLIGHTS OF PRESCRIBING INFORMATION Adults and …
www.rxabbvie.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RINVOQ safely and effectively. See full prescribing information for RINVOQ. RINVOQ® (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019 WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
docs.boehringer-ingelheim.comFULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . JARDIANCE is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. • to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Prophylaxis of DVT following hip or knee replacement ... - BMS
packageinserts.bms.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS. ELIQUIS® (apixaban) tablets, for oral use Initial U.S. Approval: 2012 WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC …
TECENTRIQ Prescribing Information - Genentech
www.gene.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Urothelial Carcinoma 1.2 Non-Small Cell Lung Cancer 1.3 Small Cell Lung Cancer 1.4 Hepatocellular Carcinoma 1.5 Melanoma 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection for Treatment of Urothelial Carcinoma, Non-Small Cell Lung Cancer and Melanoma
U. S. Department of Justice Drug Enforcement Administration
www.deadiversion.usdoj.govregistration(s) with DEA in the additional state(s) where the dispensing (including prescribing and administering) occurs, for the duration of the public health emergency declared on January 31, 2020, if authorized to dispense controlled substances by both …
NovoSeven RT PI
www.novo-pi.comTitle: NovoSeven RT PI Author: Novo Nordisk Created Date: 7/16/2020 5:58:55 AM